Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational studyArticle Published on 2022-10-082022-11-15 Journal: Lancet (London, England) [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] Abstract Admission age ambulatory patient Analysis Antiviral antiviral drug authority B.1.1.529 Case-control Charlson Comorbidity Index China Chinese clinical effectiveness Cohort Community Control COVID-19 outpatient Cox regression death Diagnosis diagnosis of SARS-CoV-2 Disease progression dominant Effectiveness glomerular filtration rate hazard Hong Kong hospitalisation HRs identify in both group In-hospital In-hospital death Infection intensive care Invasive mechanical ventilation less Logistic regression lower risk material median molnupiravir Mortality Nirmatrelvir non-hospitalised Odds ratio Older older patients outcome Outpatient Patient patients with COVID-19 primary analysis reduced risk Region Registered retrospective cohort risk Ritonavir SARS-CoV-2 SARS-COV-2 infection sensitivity analysis Sex supported the SARS-CoV-2 translation used data vaccination variant [DOI] 10.1016/S0140-6736(22)01586-0 PMC 바로가기
Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence TaskforceArticle Published on 2022-10-032022-11-15 Journal: The Medical journal of Australia [Category] COVID19(2023년), SARS, 진단, [키워드] Analysis anticoagulation Antiviral agents Baricitinib benefit change clinical clinical trial Combination coronavirus disease Corticosteroids COVID-19 disease disease severity drug treatment eight Endotracheal intubation Evidence facilitated Health include Inhaled maintain management Mild molnupiravir nine Patient people with COVID-19 positive airway pressure Primary Health Care prone positioning Prophylactic Prophylaxis Public public health randomised recommendation recommendations Remdesivir Respiratory Support sarilumab subsequent supplemental oxygen Support supportive care systemic corticosteroids therapy Tocilizumab Treatment trials Venous Thromboembolism with COVID-19 [DOI] 10.5694/mja2.51718 PMC 바로가기
Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surgeArticle Published on 2022-10-012022-11-15 Journal: American journal of transplantation : official jou [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] Administered age antiviral agent clinical trials conducted coronavirus COVID-19 COVID-19 diagnosis death diagnosed with COVID-19 Effectiveness Follow-up Healthcare systems Hospitalization kidney transplant recipients knowledge males mild-to-moderate disease molnupiravir monoclonal antibody morbidity and mortality Nirmatrelvir omicron organ Outpatient Patient Rate recipient reduced reducing retrospective SARS-CoV-2 SARS-CoV-2 pandemic single-center solid organ transplant Sotrovimab therapy [DOI] 10.1111/ajt.17098 PMC 바로가기
Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19Article Published on 2022-10-012023-07-11 Journal: Acta medica Indonesiana [Category] COVID19(2023년), [키워드] Antiviral COVID-19 molnupiravir Nirmatrelvir/ritonavir SARS-CoV-2
Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2SARS-CoV-2 Omicron subvariants, BA.1 및 BA.2에 대한 중화 항체 및 항바이러스 약물의 다양한 효능Article Published on 2022-09-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alpha Analysis antibodies antibody Antiviral antiviral drug antiviral drugs Antiviral effect antiviral effects BA.1 BA.2 Casirivimab Cell culture concentrations conserved coronavirus Delta drug treatment Efficacy EIDD-1931 Evidence FIVE Gamma Imdevimab Infection intrinsic mathematical molnupiravir Neutralizing antibodies neutralizing antibody Nirmatrelvir omicron other variant other variants quantified replacing respiratory SARS-CoV-2 sensitivity severe acute respiratory syndrome Coronavirus Sotrovimab Spread Treatment variant variants Viral [DOI] 10.1016/j.antiviral.2022.105372 PMC 바로가기 [Article Type] Article
Hospitalization as an outcome in ambulatory COVID-19 trials—not applicable in every settingDiscussion Published on 2022-09-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] clinical trials COVID-19 molnupiravir Nirmatrelvir outcome Remdesivir SARS-CoV-2 [DOI] 10.1016/j.cmi.2022.05.026 [Article Type] Discussion
Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with EpilepsyArticle Published on 2022-09-012022-11-15 Journal: Clinical pharmacokinetics [Category] COVID19(2023년), SARS, 진단, 치료제, [키워드] administration anti-SARS-CoV-2 Antiviral bidirectional boost Clinical efficacy clinically complicate Concentration Concomitant concomitant treatment country COVID-19 CYP3A4 dosing interval drug-drug interaction Efficacy European Evidence high risk information inhibitor intravenous involved medication molnupiravir Nirmatrelvir Patient patients treated persistence plasma plasma concentration Remdesivir Ritonavir severe COVID-19 disease subject substrates the SARS-CoV-2 virus Toxicity Treatment [DOI] 10.1007/s40262-022-01152-z PMC 바로가기
Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19Short communication Published on 2022-09-012022-10-05 Journal: International Journal of Infectious Diseases [Category] 임상, 치료법, 치료제, [키워드] Antiviral antiviral drug antivirals approved Assessing blockers claimed clinically COVID-19 Denmark drug drug-drug interaction Drug-drug interactions early treatment FIVE Guidance molnupiravir Nirmatrelvir/ritonavir objective patient safety Perspective predicted Prevent proportion Result risk severe COVID-19 severe COVID-19 disease severe disease statin Treatment were used [DOI] 10.1016/j.ijid.2022.06.059 [Article Type] Short communication
New Variants of SARS-CoV-2 and Next Generation of COVID-19 TreatmentsArticle Published on 2022-09-012023-07-09 Journal: Journal of clinical pharmacology [Category] COVID19(2023년), [키워드] antivirals COVID-19 molnupiravir Nirmatrelvir omicron Remdesivir [DOI] 10.1002/jcph.2067
First-generation oral antivirals against SARS-CoV-2Review article Published on 2022-09-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] COVID19(2023년), SARS, 치료제, [키워드] acute respiratory syndrome Antiviral antiviral agent Clinical practice clinical trials Compliance content coronavirus COVID-19 death drug drug-drug interaction early administration Efficacy Emergency use authorization Frequency Google Scholar high risk Hospitalization Hospitalized Immunosuppressed include individual ingestion Mild-to-moderate molnupiravir Nirmatrelvir objective oral Patient persistence progression reduced reference Regulatory required risk reduction Ritonavir SARS-CoV-2 Source Toxicity Treatment website [DOI] 10.1016/j.cmi.2022.04.015 [Article Type] Review article